科伦药业
(002422)
| 流通市值：466.33亿 | | | 总市值：570.66亿 |
| 流通股本：13.06亿 | | | 总股本：15.98亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 16,788,775,173 | 11,827,102,257 | 6,219,417,413 | 21,453,929,237 |
| 营业收入 | 16,788,775,173 | 11,827,102,257 | 6,219,417,413 | 21,453,929,237 |
| 二、营业总成本 | 13,414,966,751 | 9,235,465,674 | 4,767,842,902 | 18,277,363,122 |
| 营业成本 | 7,973,339,959 | 5,460,300,833 | 2,746,623,888 | 10,205,534,588 |
| 税金及附加 | 208,890,927 | 137,116,833 | 63,763,665 | 302,726,528 |
| 销售费用 | 2,614,400,264 | 1,918,281,105 | 1,101,758,680 | 4,449,718,404 |
| 管理费用 | 979,692,555 | 614,302,424 | 336,048,506 | 1,142,052,035 |
| 研发费用 | 1,584,138,271 | 1,078,120,396 | 502,816,867 | 1,943,570,077 |
| 财务费用 | 54,504,775 | 27,344,083 | 16,831,296 | 233,761,490 |
| 其中:利息费用 | 123,591,837 | 89,506,124 | 47,635,913 | 361,538,172 |
| 其中:利息收入 | 55,953,080 | 40,964,765 | 22,314,195 | 103,592,175 |
| 加:公允价值变动收益 | 13,677,065 | 5,465,160 | 2,938,945 | 14,666,354 |
| 加:投资收益 | 288,265,130 | 213,759,100 | 111,835,302 | 358,881,875 |
| 资产处置收益 | 879,447 | 1,371,060 | 646,018 | 2,626,645 |
| 资产减值损失(新) | -30,499,004 | -26,047,377 | 0 | -130,550,972 |
| 信用减值损失(新) | -76,794,845 | -69,697,693 | -46,365,589 | -45,984,834 |
| 其他收益 | 240,643,276 | 195,455,017 | 111,819,017 | 277,937,975 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 3,809,979,491 | 2,911,941,850 | 1,632,448,204 | 3,654,143,158 |
| 加:营业外收入 | 6,162,674 | 3,054,053 | 1,693,421 | 11,855,064 |
| 减:营业外支出 | 110,480,202 | 49,928,518 | 9,346,453 | 85,572,172 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 3,705,661,963 | 2,865,067,385 | 1,624,795,172 | 3,580,426,050 |
| 减:所得税费用 | 784,656,386 | 649,288,497 | 338,993,759 | 933,786,688 |
| 六、净利润 | 2,921,005,577 | 2,215,778,888 | 1,285,801,413 | 2,646,639,362 |
| 持续经营净利润 | 2,921,005,577 | 2,215,778,888 | 1,285,801,413 | 2,646,639,362 |
| 归属于母公司股东的净利润 | 2,470,927,259 | 1,800,111,225 | 1,026,188,176 | 2,456,112,045 |
| 少数股东损益 | 450,078,318 | 415,667,663 | 259,613,237 | 190,527,317 |
| (一)基本每股收益 | 1.57 | 1.15 | 0.67 | 1.69 |
| (二)稀释每股收益 | 1.57 | 1.15 | 0.67 | 1.59 |
| 八、其他综合收益 | -17,620,214 | 20,299,128 | -845,212 | -60,842,218 |
| 归属于母公司股东的其他综合收益 | -13,921,396 | 20,148,034 | -1,446,988 | -60,369,779 |
| 九、综合收益总额 | 2,903,385,363 | 2,236,078,016 | 1,284,956,201 | 2,585,797,144 |
| 归属于母公司股东的综合收益总额 | 2,457,005,863 | 1,820,259,259 | 1,024,741,188 | 2,395,742,266 |
| 归属于少数股东的综合收益总额 | 446,379,500 | 415,818,757 | 260,215,013 | 190,054,878 |
| 公告日期 | 2024-10-29 | 2024-08-29 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |